Evidence map›Paper›PMID 35515680›Full record

ArticleRSC advances2020

Hybrid red blood cell membrane coated porous silicon nanoparticles functionalized with cancer antigen induce depletion of T cells.

Antti Rahikkala, Flavia Fontana, Tomás Bauleth-Ramos, Alexandra Correia, Marianna Kemell, Jani Seitsonen, Ermei Mäkilä, Bruno Sarmento, Jarno Salonen, Janne Ruokolainen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 6 countries.

Antti RahikkalaDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki Finland antti.rahikkala@helsinki.fi helder.santos@helsinki.fi.ORCID https://orcid.org/0000-0003-3846-3249
Flavia FontanaDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki Finland antti.rahikkala@helsinki.fi helder.santos@helsinki.fi.
Tomás Bauleth-RamosInstituto de Investigação e Inovação em Saúde (I3S), University of Porto Rua Alfredo Allen, 208 4200-135 Porto Portugal.
Alexandra CorreiaDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki Finland antti.rahikkala@helsinki.fi helder.santos@helsinki.fi.
Marianna KemellDepartment of Chemistry, University of Helsinki FI-00014 Helsinki Finland.ORCID https://orcid.org/0000-0002-3583-2064
Jani SeitsonenNanomicroscopy Center, Aalto University FI-02150 Espoo Finland.
Ermei MäkiläLaboratory of Industrial Physics, Department of Physics, University of Turku FI-20014 Turku Finland.
Bruno SarmentoCESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde 4585-116 Gandra Portugal.ORCID https://orcid.org/0000-0001-5763-7553
Jarno SalonenLaboratory of Industrial Physics, Department of Physics, University of Turku FI-20014 Turku Finland.
Janne RuokolainenNanomicroscopy Center, Aalto University FI-02150 Espoo Finland.
Jouni HirvonenDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki Finland antti.rahikkala@helsinki.fi helder.santos@helsinki.fi.
Hélder A SantosDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki Finland antti.rahikkala@helsinki.fi helder.santos@helsinki.fi.ORCID https://orcid.org/0000-0001-7850-6309
University of Helsinki · FIScientific Research Institute of Introscopy · RUUniversity of Turku · FICooperativa de Ensino Superior Politécnico e Universitário · PTUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythrocyte-based drug delivery systems have been investigated for their biocompatibility, long circulation time, and capability to transport cargo all around the body, thus presenting enormous potential in medical applications. In this study, we investigated hybrid nanoparticles consisting of nano-sized autologous or allogeneic red blood cell (RBC) membranes encapsulating porous silicon nanoparticles (PSi NPs). These NPs were functionalized with a model cancer antigen TRP2, which was either expressed on the surface of the RBCs by a cell membrane-mimicking

Identifiers

PMID35515680
PMCPMC9056825
OpenAlexW3087799822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.